APRIL 2023LIFE SCIENCES REVIEW2We have the people, skills, and knowledge to take a project from concept to end product· Country specific HTA submissions in over 28 countries· Global value dossiers (GVD)· Early access and highly specialized programs· Clinical study reports· Payer objection handlers· Posters and abstracts· Manuscripts and publications· Slide presentations (PowerPoint)Value CommunicationOur Network of Specialists · Advisory boards· Early Access to Medicines program development· Academic and industry subject matter experts· Regulatory support Health Economics · Developing innovative models, including: · Cost-utility · Cost-minimization · Budget impact· Country adaptions of models· Model auditing and optimizationReal World Evidence (RWE) · Systematic literature review (SLR)· Database analysis· Retrospective and observational studies· Indirect treatment comparison (ITC)/ Network meta-analysis (NMA) Market Access Strategy · Strategic positioning· Value story development· HEOR tactical planning· Evidence generation planningWith our core team of senior consultants in Europe, the US and Canada, IMAC is positioned to overcome your market accesschallenges worldwideWith experience in over 28+ countries, IMAC has developed successful submissions in allthe major European, EMEA, and Australian/Asian markets!MAC has a track record of success in the UK, with submissions to NICE (including the more recent HST pathway) and Early Access Programs--both of which are key for rare disease therapies!IMAC is well versed in the US pathway, including considerable experience with AMCPand private payer submissions!Our consultants have direct experience within CADTH, INESSS, hospital P&T, and the private payer systems in Canada!Evidence GenerationBurden of Diseaseand Unmet NeedClinicaland EconomicVALUESTORYSTRATEGY
< Page 1 | Page 3 >